Mauna Kea Technologies today announced its financial results for the full year ended December 31, 2016, as approved by the Board of Directors at its meeting on March 21, 2017. The Company will host a conference call today to discuss the full year 2016 results and provide an update on its business
Mauna Kea Technologies, inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, today confirmed it is eligible to the PEA-PME investment vehicles, according to decree n° 2014‐283 dated 4 March 2014, ruling on the PEA-PME eligibility criteria for companies.
Paris, France, March 20, 2017 - Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, announced today that it will publish its results for the full year ended December 31, 2016 on Thursday, March 23, 2017 at 5:45 PM CET (Paris time).
Mauna Kea Technologies announced today the appointment for Jennifer F. Tseng, M.D., M.P.H., as an Independent Director, effective immediately. Dr. Tseng currently serves as Chief, Division of Surgical Oncology at Beth Israel Deaconess Medical Center in Boston and Clinical Co-Director for Surgery at the Cancer Center at Beth Israel Deaconess Medical Center. Dr. Tseng is also a Professor of Surgery at the Harvard Medical School.
Mauna Kea Technologies announced a new peer-reviewed publication from the Singapore Gastric Cancer Consortium highlighting the excellent results utilizing Cellvizio in improving diagnostic yield in gastric cancer, including the need for two-thirds fewer biopsies to confirm the presence of disease. The publication includes a meta-analysis of studies utilizing CLE with Cellvizio in gastric diseases, demonstrating superior results compared to conventional imaging modalities also evaluated in the study, including chromoendoscopy and narrow band imaging.
Mauna Kea Technologies today announced that it has secured a non-dilutive, €7.0 million senior debt financing with IPF Partners, a leading provider of alternative financing solutions for emerging, commercial-stage European healthcare companies.